Page last updated: 2024-10-24

carisoprodol and Cystic Fibrosis of Pancreas

carisoprodol has been researched along with Cystic Fibrosis of Pancreas in 1 studies

Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)
carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chung, WJ1
Goeckeler-Fried, JL1
Havasi, V1
Chiang, A1
Rowe, SM1
Plyler, ZE1
Hong, JS1
Mazur, M1
Piazza, GA1
Keeton, AB1
White, EL1
Rasmussen, L1
Weissman, AM1
Denny, RA1
Brodsky, JL1
Sorscher, EJ1

Other Studies

1 other study available for carisoprodol and Cystic Fibrosis of Pancreas

ArticleYear
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu

2016